What's Old Is New Again: Bacteriophage Therapy in the 21st Century

Saima Aslam; Robert T Schooley

doi:10.1128/AAC.01987-19

What's Old Is New Again: Bacteriophage Therapy in the 21st Century

Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01987-19. doi: 10.1128/AAC.01987-19. Print 2019 Dec 20.

Authors

Saima Aslam¹, Robert T Schooley²

Affiliations

¹ Division of Infectious Diseases and Global Public Health, Center for Innovative Phage Applications and Therapeutics, University of California, San Diego, San Diego, California saslam@ucsd.edu.
² Division of Infectious Diseases and Global Public Health, Center for Innovative Phage Applications and Therapeutics, University of California, San Diego, San Diego, California.

Abstract

We highlight features associated with bacteriophage therapy that make it an attractive treatment option for multidrug-resistant infections and also discuss some of the challenges that need to be considered in the design and execution of clinical trials directed at evaluating the efficacy of bacteriophage therapy in humans.

Keywords: antimicrobial resistance (AMR); bacteriophage therapy; multidrug resistance (MDR); phage therapy.

Publication types

Comment

MeSH terms

Anti-Bacterial Agents
Bacteriophages*
Drug Resistance, Multiple, Bacterial / drug effects
Humans
Phage Therapy*
Prosthesis-Related Infections*
Pseudomonas aeruginosa / drug effects

Substances

Anti-Bacterial Agents